Geographic distance and patient complexity shaped reperfusion after STEMI in Norway
Among 7,607 patients with ST-segment elevation myocardial infarction registered in Norway between 2015 and 2018, only 56% received reperfusion within recommended time limits. The national target is 85%, leaving a wide gap between policy and practice in a condition where every minute of coronary occlusion increases myocardial loss. The most striking contrast appeared across hospital referral areas: 81% of patients in the Oslo referral area received timely reperfusion, while only 13% of patients in Finnmark did so. Those figures describe more than variation in logistics. They point to a system in which geography can determine whether a patient reaches primary PCI or fibrinolysis soon enough to preserve myocardium.
The study used a national register-based cohort design and multilevel logistic regression to examine how residency, patient characteristics, and socio-economic factors related to timely reperfusion. In a disease driven by abrupt coronary thrombosis, treatment speed depends on both symptom recognition and transport capacity. The pathway from symptom onset to first medical contact, then from first contact to reperfusion, is especially vulnerable to delay when patients live far from a PCI centre. Norway’s long distances and remote communities make that issue clinically unavoidable, and the data quantify its effect with unusual clarity.
Travel time to a PCI centre carried a steep penalty
Travel time to a PCI centre showed one of the strongest associations in the analysis. Compared with travel times of less than 1 hour, an interval of 1 to 2 hours was linked to markedly lower odds of timely reperfusion, with an odds ratio of 0.39. Travel times beyond 2 hours lowered the odds even further, to 0.22. In practical terms, the probability of meeting guideline time limits fell sharply as distance increased. The biological logic is straightforward: the longer the artery remains occluded, the greater the extent of irreversible myocardial necrosis, and the less salvageable the endangered tissue becomes. A delay of this kind does not merely reduce procedural convenience; it alters infarct size, ventricular function, and the downstream burden of heart failure.
The same pattern makes the case for prehospital decision-making. If a patient is far from an invasive centre, waiting to initiate care only after hospital arrival can waste the narrow window in which reperfusion has the greatest benefit. The authors’ conclusion points toward expanded use of a prehospital pharmacoinvasive strategy, a pathway that can begin fibrinolytic treatment earlier when timely primary PCI is not realistically available. In a country with large geographic spread, the issue is not whether advanced PCI matters. It is whether the system can deliver reperfusion quickly enough when direct transfer is no longer the fastest option.
Age, comorbidity, and delay to first medical contact also reduced odds
Clinical vulnerability was not distributed evenly. Patients aged 75 to 84 years had lower odds of timely reperfusion than patients younger than 55 years, with an odds ratio of 0.73. Patients with moderate comorbidity had lower odds than those without comorbidity, and the reduction was greater still in those with high comorbidity, where the odds ratio fell to 0.61. These findings fit bedside reality. Older patients and those carrying multiple chronic illnesses often present with more diagnostic ambiguity, greater frailty, or competing acute problems that can slow triage and transport decisions. Symptom interpretation may also be less straightforward, which can delay activation of the reperfusion pathway.
Delay before first medical contact mattered as well. More than 2 hours from symptom onset to first medical contact was associated with lower odds of timely reperfusion than less than 30 minutes, with an odds ratio of 0.63. That delay represents a critical early failure point, because the system cannot treat an infarct until the patient enters the chain of emergency care. Public recognition of myocardial infarction symptoms, rapid emergency activation, and efficient prehospital assessment all become part of the reperfusion strategy. In STEMI, the clock starts before the ambulance is called.
The Oslo-Finnmark gap reveals a structural access problem
Regional differences were so large that they cannot be dismissed as statistical noise. The Oslo referral area reached timely reperfusion in a setting where rapid access to PCI is likely far more feasible, while Finnmark lagged dramatically behind. These are not simply differences in patient preference or individual behavior. They reflect how infrastructure, distance, and system organization shape access to a time-dependent intervention. When a national health policy sets a high standard for reperfusion timing, persistent regional failure to meet that standard becomes an equity problem as much as a performance problem.
This matters because reperfusion is one of the most time-sensitive treatments in modern cardiology. The benefit of opening an occluded coronary artery erodes with delay, and the penalty for distance is especially severe in remote settings. A patient in a large urban referral area can move from first medical contact to catheterization within a window that preserves more myocardium. A patient living hours from a PCI centre may face a structurally different course, even when symptoms are recognized promptly. The study makes that asymmetry visible in national data rather than anecdote.
Prehospital fibrinolysis may close part of the gap
The authors point to expanded use of prehospital pharmacoinvasive treatment as a way to improve timely reperfusion in Norway. That approach makes clinical sense in regions where direct PCI transfer cannot reliably meet time targets. Early fibrinolysis can restore coronary flow before transport to a PCI-capable centre for subsequent angiography and intervention. The strategy does not replace PCI in systems that can provide it quickly, but it offers a practical alternative when geography works against timely catheter-based care.
For clinicians and health planners, the implication is direct. Regions with long travel times need reperfusion pathways built around time, not around geography alone. The study shows that current delivery does not meet the national target and does so unevenly across the country. It also shows which patients are most likely to fall behind: older adults, those with substantial comorbidity, and those who live far from PCI centres. Together, those findings identify where system redesign could have the greatest effect.
The analysis does not solve the implementation problem, and it does not measure individual clinical outcomes such as infarct size or mortality in this dataset. What it does show is harder to ignore: a national reperfusion strategy can still leave major pockets of avoidable delay when distance and referral structure dominate access. In STEMI care, that delay is not abstract. It is myocardium lost before treatment begins.